Brunch seminar

Brunch seminar on ultra sensitive proteomics for research on neurological conditions

The session will introduce the Alamar NULISA proteomics panels, enabling highly sensitive measurement of biomarkers for neurodegeneration and inflammation. The programme includes presentations on NULISA biomarker profiling in longitudinal studies, pilot results on dementia risk prediction in UK Biobank, and technical features of the NULISA proteomics panels.
NULISA technology is now available in Finland through a partnership between Alamar Biosciences and Nightingale Health.
Brunch will be served beforehand (from 10:30 in Lobby C1).
There will be time for discussion on scientific applications, technology, and pricing. 
Please see the scientific programme below. I hope to see you there!
10:30–11:00 Registration and brunch (Biomedicum, Lobby C1)
11:00–11:20 Dr. Eero Vuoksimaa (FIMM): NULISA proteomic profiling of neurodegeneration in longitudinal settings
11:20–11:30 Dr. Peter Würtz (Nightingale Health):  A pilot study using NULISA in UK Biobank to predict dementia risk already at midlife
11:30–11:40 Dr. Nikolaos Tertipis (Alamar Biosciences): Unlock the power of precision proteomics for research on neurodegeneration, inflammatory response, and beyond
11:40–12:00 Q&A on NULISA proteomics – now available in Finland from Nightingale Health lab
Link to registration
https://www.lyyti.in/NULISA_seminar